The major histocompatibility complex (MHC) is crucial to the adaptive immune response of vertebrates and is among the most polymorphic gene families known. Its high diversity is usually attributed to selection imposed by fast-evolving pathogens. Pathogens are thought to evolve to escape recognition by common immune alleles, and, hence, novel MHC alleles, introduced through mutation, recombination, or gene flow, are predicted to give hosts superior resistance. Although this theoretical prediction underpins host-pathogen "Red Queen" coevolution, it has not been demonstrated in the context of natural MHC diversity. Here, we experimentally tested whether novel MHC variants (both alleles and functional "supertypes") increased resistance of guppies () to a common ectoparasite (). We used exposure-controlled infection trials with wild-sourced parasites, and -naïve host fish that were F descendants of crossed wild populations. Hosts carrying MHC variants (alleles or supertypes) that were new to a given parasite population experienced a 35-37% reduction in infection intensity, but the number of MHC variants carried by an individual, analogous to heterozygosity in single-locus systems, was not a significant predictor. Our results provide direct evidence of novel MHC variant advantage, confirming a fundamental mechanism underpinning the exceptional polymorphism of this gene family and highlighting the role of immunogenetic novelty in host-pathogen coevolution.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816137 | PMC |
http://dx.doi.org/10.1073/pnas.1708597115 | DOI Listing |
Cancer Immunol Immunother
January 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, People's Republic of China.
The development of tumor vaccines represents a significant focus within cancer therapeutics research. Nonetheless, the efficiency of antigen presentation in tumor vaccine remains suboptimal. We introduce an innovative mRNA-lipid nanoparticle platform designed to express tumor antigenic epitopes fused with the transmembrane domain and cytoplasmic tail of the neonatal Fc receptor (FcRn).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Columbia University Medical Center, New York, NY, USA.
Background: The immunoproteasome (IP) is the inducible form of the constitutive 20S proteasome upregulated in immune cells. The IP consists of 3 inducible β subunits (β1i - LMP2, β2i - MECL1, and β5i - LMP7), which generate MHC-I compatible peptides. IPs are induced by pro-inflammatory cytokine signaling, as well as oxidative stress signaling.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Background: We have found that the MHC class I-like MR1 molecule and the innate-like T cells that recognize them (MAIT-mucosal-associated invariant T cells) contribute to the development of pathology in Alzheimer's disease (AD). Moreover, we find elevated levels of MR1 expression and increased numbers of MAIT cells in the brains of 5XFAD mice overtime; these MAIT cells express high surface levels of the T cell activation markers, CD25 and CD69. Here, we are focused on how these two phenomena are connected in AD pathology.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Traditional immunotherapies mainly focus on αβ T cell-based strategies, which depend on MHC-mediated antigen recognition. However, this approach poses significant challenges in treating recurrent tumors, as immune escape mechanisms are widespread. γδ T cells, with their ability for MHC-independent antigen presentation, offer a promising alternative that could potentially overcome limitations observed in traditional immunotherapies.
View Article and Find Full Text PDFJ Am Chem Soc
January 2025
State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
Despite the promising clinical applications of immunotherapy, its effectiveness is often limited by low immune responses and tumor immune escape. In this study, we introduce a simple and drug-free inorganic nanomaterial, sodium succinate (CHNaO NPs), prepared using a rapid microemulsion method to enhance cancer immunotherapy. The synthesized CHNaO NPs can release high concentrations of Na and succinate ions into tumor cells, leading to an increase in intracellular osmolarity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!